 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of...

Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates

Enveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023

Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety...

Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives

Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives

Enveric Biosciences to Present at H.C. Wainwright 25th Annual Global Conference

Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs

The USPTO issued a patent covering Enveric Biosciences (NASDAQ: ENVB) lead candidate EB-373, a psilocin prodrug under development for the treatment of anxiety disorder.
read more...

Boosting Next-Gen Mental Health Care: Enveric's New US Patent For Anxiety Treatment

NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Enveric Biosciences Inc. (NASDAQ: ENVB). The in-depth 23-page initiation report includes detailed information on the ...

Diamond Equity Research Initiates Coverage on Enveric Biosciences Inc. (NASDAQ: ENVB)

Enveric Biosciences, Inc. (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of...

Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results

Next-gen psychedelics business Enveric Biosciences (NASDAQ: ENVB) reported its unaudited financial results for the second quarter of 2023 ended June 30.
Resultsshow:
read more...

Enveric's Q2 2023 Financials Show Immediate Need For Budget-Slimming Toward A Clinical-Staged 2024

Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. The company is headquartered in Naples, FL.

Watchers	14,024
52-Wk Low	$1.30
52-Wk High	$6.98

Market Cap	$5.18M
Volume (M)	65,333.00
52-Wk High	$6.98
52-Wk Low	$1.30

ENVB Enveric Biosciences Inc

About

Feed

News

Sentiment

Fundamentals